A number of firms have modified their ratings and price targets on shares of Cytokinetics, (NASDAQ: CYTK) recently:

  • 8/4/2017 – Cytokinetics, had its “buy” rating reaffirmed by analysts at Cowen and Company. They now have a $19.00 price target on the stock. They wrote, “CYTK reported a Q2 loss of $29.1MM and ended the quarter with $332MM in cash.””
  • 8/3/2017 – Cytokinetics, was given a new $26.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 7/31/2017 – Cytokinetics, is now covered by analysts at Morgan Stanley. They set an “overweight” rating and a $24.00 price target on the stock.
  • 7/25/2017 – Cytokinetics, was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 7/17/2017 – Cytokinetics, was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “sell” rating. According to Zacks, “Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics’ lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. “
  • 7/13/2017 – Cytokinetics, was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 7/11/2017 – Cytokinetics, was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $14.00 price target on the stock. According to Zacks, “Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics’ lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. “

Cytokinetics, Incorporated (NASDAQ:CYTK) traded down 2.09% during mid-day trading on Monday, hitting $12.90. The stock had a trading volume of 279,611 shares. The company’s 50 day moving average price is $13.67 and its 200 day moving average price is $12.95. Cytokinetics, Incorporated has a 52 week low of $8.51 and a 52 week high of $17.20. The firm’s market cap is $622.00 million.

Cytokinetics, (NASDAQ:CYTK) last released its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.57) by $0.03. Cytokinetics, had a negative net margin of 16.00% and a negative return on equity of 14.15%. The business had revenue of $3.05 million during the quarter, compared to analysts’ expectations of $5.28 million. Analysts anticipate that Cytokinetics, Incorporated will post ($2.02) earnings per share for the current year.

In other Cytokinetics, news, CEO Robert I. Blum sold 5,000 shares of the firm’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $12.14, for a total value of $60,700.00. Following the sale, the chief executive officer now owns 88,385 shares of the company’s stock, valued at approximately $1,072,993.90. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders sold 15,000 shares of company stock worth $197,750. Insiders own 7.20% of the company’s stock.

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Receive News & Ratings for Cytokinetics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.